New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...

Boston Scientific has secured label expansion from FDA for its Watchman FLX and Watchman FLX Pro. The Marlborough, MA-based company had already expected the label expansion, which now includes ...

More special care is needed when using the Watchman access systems used to deliver transcatheter left atrial appendage (LAA) closure devices due to a risk for air embolisms, according to an FDA alert.

Approximately 10.5 million Americans have atrial fibrillation (AFib), a condition that causes an irregular, often too fast, ...

An observational study linked percutaneous LAA occlusion peridevice leaks, whether larger or smaller than 3 mm, with stroke and other adverse events. Researchers highlighted the clinical significance ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, ...